Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials

Aim: Obesity is a global epidemic. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. Clinical trials of GLP-1/GIP/glucagon(GCG) triple agon...

Full description

Saved in:
Bibliographic Details
Main Authors: Haoyang Guo, Juan Yang, Jihan Huang, Ling Xu, Yinghua Lv, Yexuan Wang, Jiyuan Ren, Yulin Feng, Qingshan Zheng, Lujin Li
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Obesity Pillars
Subjects:
GLP-1RA
Model-based meta-analysis
Obesity
Weight reduction
Online Access:http://www.sciencedirect.com/science/article/pii/S2667368125000063
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items